Solmaz ÇELEBİ, Mustafa Kemal HACIMUSTAFAOĞLU, Yücehan ALBAYRAK, Ayşe Melda SINIRTAŞ

Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years

Hepatitis A can be prevented by vaccination. The aim of this study was to determine seropositivity for hepatitis A before vaccination in healthy children 12 and 24 months of age and compare seroconversion rates after vaccination between these 2 groups. Materials and methods: Forty-nine children aged 1 year (Group 1) and 51 children aged 2 years (Group 2) were included in the study. Inactive hepatitis A vaccine (Avaxim, 80 antigenic subtypes, 0.5 mL) were administered to every child in 2 doses, 6 months apart. Anti-hepatitis A virus (HAV) IgG and IgM antibodies were detected by Architect HAVAb-IgG and HAVAb-IgM (Abbott, Wiesbaden, Germany) test kits. Results: Nine percent of the children were seropositive for anti-HAV IgG before vaccination. The seroconversion rate at 2 weeks was 34% and 44% in Group 1 and Group 2, respectively. At 4 weeks the seroconversion rate was 87.7% and 90.1% in Group 1 and Group 2, respectively. All of the children who completed the vaccination program were seropositive at 28 weeks (after the second dose). No serious adverse reaction was observed in any of the children. Conclusion: It was determined that Avaxim, including 80 antigen units, is safe and immunogenic in healthy children 12 and 24 months of age.

Anahtar Kelimeler:

Key words: Hepatitis A vaccine, seroprevalence, safety, immunogenicity, children

Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years

Keywords:

Key words: Hepatitis A vaccine, seroprevalence, safety, immunogenicity, children,

PDF

___

Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. pp.1577–92.
Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat 2008; 15: S69–72.
Alabaz D, Aksaray N, Alhan E, Yaman A. Decline of maternal hepatitis A antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg 2005; 73: 457–9.
Vidor E. Vaccination of newborns against hepatitis A in the presence of maternally derived antibodies. J Comp Path 2007; 137: S42–5.
Lieberman JM, Chang SJ, Partridge S, Hollister JC, Kaplan KM, Jensen EH et al. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 2002; 21: 347–8.
Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004; 144: 327–2.
Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology 2012; 56: 516–
American Academy of Pediatrics Committee on Infectious Disease. Hepatitis A vaccine recommendations. Pediatrics 2007; 120: 189–99.
Vitral CL, Ospina FLN, Artimos S, Melgaço JG, Cruz OG, Salete de Paula V et al. Declining prevalence of hepatitis A virus antibodies among children from low socioeconomic groups reinforces the need for the implementation of hepatitis A vaccination in Brazil. Mem Inst Oswaldo Cruz 2012; 107: 652–
Verma R, Khanna P. Hepatitis A vaccine should receive priority in national immunization schedule in India. Hum Vaccin Immunother 2012; 8: 1132–4.
ABBOTT. HAVAb IgG Architect System. Wiesbaden, Germany: ABBOTT Diagnostic Division; 2004.
Bell BP, Wasley A, Feinstone SM. Hepatitis A virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. pp.2367–87.
Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004; 132: 1005–22.
Steffen R. Changing travel-related global epidemiology of hepatitis A. Am J Med 2005; 118: S46–9.
Roy E, Haley N, Leclerc P, Cedras L, Bedard L, Allard R. Seroprevalence and risk factors for hepatitis A among Montreal street youth. Can J Public Health 2002; 93: 52–3.
Payment P. Antibody levels to selected enteric viruses in a French-Canadian population in the province of Quebec (Canada). Immunol Infect Dis 1991; 1: 317–22.
Kanra G, Tezcan S, Badur S. Turkish National Study Team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr 2002; 44: 204–10.
Yapicioglu H, Alhan E, Yildizdaş D, Yaman A, Bozdemir N. Prevalence of hepatitis A in children and adolescents in Adana, Turkey. Indian Pediatr 2002; 39: 936–41.
Ince OT, Yalçin SS, Yurdakök K, Ozmert EN. Hepatitis A seroprevalence among infants aged 12 months in Ankara. Turk J Pediatr 2011; 53: 114–6.
Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007; 26: 116–22.
Hacımustafaoğlu M, Sadıkoğlu G, Özakın C, Akın N, Çavuşoğlu B, Ercan İ et al. Maternal hepatitis A antibodies in infants. Bursa Devlet Hastanesi Bülteni 1999; 15: 143–6.
Lopez EL, Del Carmen Xifro M, Torrado LE, De Rosa MF, Gómez R, Dumas R et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 2001; 20: 48–52.
Sjogren MH, Hoke CH, Binn LN, Eckels KH, Dubois DR, Lyde L et al. Immunogenicity of an inactivated hepatitis A vaccine. Ann Intern Med 1991; 114: 470–1.
Aristegui J, Morales JL, Dal-Re R, Gonzalez A, Gallego MS, Garrote E. Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old. Infection 1995; 23; 334–8.
Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995; 171: S70–2.
Lee CY, Huang LM, Lee PI, Chiu HH, Dumas R, Milcamps B et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Southeast Asian J Trop Med Public Health 2000; 31: 29–36.